Kangmei Pharmaceutical Co., Ltd. Share Price

Equities

600518

CNE0000017M1

Pharmaceuticals

End-of-day quote Shanghai S.E. 23:00:00 16/05/2024 BST 5-day change 1st Jan Change
1.95 CNY +0.52% Intraday chart for Kangmei Pharmaceutical Co., Ltd. -0.51% +4.84%

Financials

Sales 2022 4.18B 579M 45.6B Sales 2023 4.87B 675M 53.17B Capitalization 25.79B 3.57B 281B
Net income 2022 -2.69B -372M -29.33B Net income 2023 103M 14.26M 1.12B EV / Sales 2022 7 x
Net cash position 2022 1.24B 172M 13.57B Net cash position 2023 802M 111M 8.75B EV / Sales 2023 5.13 x
P/E ratio 2022
-11.6 x
P/E ratio 2023
186 x
Employees 4,409
Yield 2022 *
-
Yield 2023
-
Free-Float 67.98%
More Fundamentals * Assessed data
Dynamic Chart
Kangmei Pharmaceutical Logs Profit in Q1 MT
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Kangmei Pharmaceutical Returns to Profit in 2023; Shares Decline 4% MT
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Court Dismisses Winding-Up Petition Against Kangmei Pharma's Unit MT
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
China’s Securities Regulator Fines 37 Brokerages Since H1 2019 MT
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Former Kangmei Chairman Loses Appeal Against 12-Year Sentence MT
Kangmei Pharmaceutical Co., Ltd. announced that it has received CNY 6.5 billion in funding from Guangdong Shennong Enterprise Management Partnership (Limited Partnership), GF Securities Co., Ltd., Investment Arm, Wuhu Xintongrui Enterprise Management Center (Limited Partnership), Shenzhen Zhaoping Linghang Investment Center (Limited Partnership), China Resources Shenzhen International Investment Trust Co., Ltd. CI
More news
1 day+0.52%
1 week-0.51%
Current month-2.01%
1 month+3.17%
3 months+4.84%
6 months+4.28%
Current year+4.84%
More quotes
1 week
1.93
Extreme 1.93
1.99
1 month
1.88
Extreme 1.88
2.04
Current year
1.68
Extreme 1.68
2.33
1 year
1.68
Extreme 1.68
2.42
3 years
1.68
Extreme 1.68
5.16
5 years
1.66
Extreme 1.66
6.31
10 years
1.66
Extreme 1.66
28.25
More quotes
Managers TitleAgeSince
Chief Executive Officer 51 09/10/20
Director of Finance/CFO 50 09/10/20
Investor Relations Contact 35 31/12/18
Members of the board TitleAgeSince
Director/Board Member 63 29/10/20
Chairman 59 29/10/20
Director/Board Member 62 24/01/22
More insiders
Date Price Change Volume
17/05/24 1.95 +0.52% 44,688,890
16/05/24 1.94 0.00% 55,943,980
15/05/24 1.94 0.00% 61,119,930
14/05/24 1.94 -1.52% 124,373,700
13/05/24 1.97 -1.50% 65,882,050

End-of-day quote Shanghai S.E., May 16, 2024

More quotes
Kangmei Pharmaceutical Co., Ltd. develops, produces, and sells pharmaceutical products intended primarily for treating hypertension and colds. The group offers Chinese medications (ginseng, salvia, codonopsis, etc.) and chemical medications (clarithromycin, doxazosin mesylate, paracetamol, etc.). All sales are earned in China.
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 600518 Stock